Literature DB >> 30323981

Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Xiaowen Tang1,2,3, Lin Yang3,4,5, Zheng Li1,2,3, Ansel P Nalin6, Haiping Dai1,2,3, Ting Xu1,2,3, Jia Yin1,2,3, Fengtao You3,4,5, Mingqing Zhu1,2,3, Wenhong Shen1,2,3, Guanghua Chen1,2,3, Xiaming Zhu1,2,3, Depei Wu1,2,3, Jianhua Yu6,7,8.   

Abstract

[This corrects the article on p. 1083 in vol. 8, PMID: 30034945.].

Entities:  

Year:  2018        PMID： 30323981      PMCID： PMC6176185     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN： 2156-6976            Impact factor:   6.166


  11 in total

1.  Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells.

Authors:  Grace Lee; Sheela Karunanithi; Bruce Posner; Hanspeter Niederstrasser; Hong Cheng; Yuriy Federov; Shivaprasad Manjappa; Karam Musaitif; Huaiyu Wang; Zachary Jackson; David Wald
Journal:  Cancer Immunol Immunother       Date:  2021-11-23       Impact factor: 6.630

2.  Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.

Authors:  Yan Liu; Yehui Zhou; Kuo-Hsiang Huang; Xujie Fang; Ying Li; Feifei Wang; Li An; Qingfei Chen; Yunchao Zhang; Aihua Shi; Shuang Yu; Jingzhong Zhang
Journal:  Cell Prolif       Date:  2020-06-27       Impact factor: 6.831

Review 3.  Emerging Immunotherapy for Acute Myeloid Leukemia.

Authors:  Rikako Tabata; SungGi Chi; Junichiro Yuda; Yosuke Minami
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

Review 4.  Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress.

Authors:  Yixi Zhang; Pan Li; Hongyu Fang; Guocan Wang; Xun Zeng
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

Review 5.  Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.

Authors:  Faroogh Marofi; Heshu Sulaiman Rahman; Lakshmi Thangavelu; Aleksey Dorofeev; Favian Bayas-Morejón; Naghmeh Shirafkan; Navid Shomali; Max Stanley Chartrand; Mostafa Jarahian; Ghasem Vahedi; Rebar N Mohammed; Somayeh Shahrokh; Morteza Akbari; Farhad Motavalli Khiavi
Journal:  Stem Cell Res Ther       Date:  2021-03-22       Impact factor: 6.832

Review 6.  Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering.

Authors:  Yishan Ye; Luxin Yang; Xiaolin Yuan; He Huang; Yi Luo
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

Review 7.  Engineered NK Cells Against Cancer and Their Potential Applications Beyond.

Authors:  Maria Karvouni; Marcos Vidal-Manrique; Andreas Lundqvist; Evren Alici
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

Review 8.  Immunotherapy in AML: a brief review on emerging strategies.

Authors:  A Moeinafshar; S Hemmati; N Rezaei
Journal:  Clin Transl Oncol       Date:  2021-06-23       Impact factor: 3.405

Review 9.  Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer.

Authors:  Xiaoyan Zhao; Li Cai; Yu Hu; Huafang Wang
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

10.  Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases.

Authors:  Stefan Grote; Frank Traub; Joerg Mittelstaet; Christian Seitz; Andrew Kaiser; Rupert Handgretinger; Sabine Schleicher
Journal:  Cancers (Basel)       Date:  2021-03-05       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.